TORONTO, Oct. 2, 2023 - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs") a company specialized in precision-based cannabinoids, is pleased to announce it has entered into a settlement agreement on September 29, 2023 (the "Settlement Agreement") to resolve a claim in connection with a commercial ag... Read More...

The launch includes GMP strain-specific full spectrum cannabis oil and inhalation cartridge products to be distributed to patients under the MediPharm Labs Beacon Medical brand.  As of July 2023, all Australian medical cannabis products must meet strict pharmaceutical GMP standards. MediPharm Labs is one of the few companies already meet... Read More...

MediPharm Labs and Shelter Cannabis Brands have terminated their royalty agreement with a one-time cash payment. Agreement includes the elimination of ongoing royalty payments, for a one-time lump sum payment. TORONTO, Sept. 20, 2023 - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs") a company s... Read More...

MediPharm Labs sold vacant land in Napanee, Ontario last utilized in 2021 for outdoor cannabis growing activities. The land was acquired by MediPharm as part of the VIVO Cannabis acquisition in April 2023. The net cash proceeds of $1.9 million adds non-dilutive capital to MediPharm's strong balance sheet. The $1.9 million cash is in addi... Read More...

MediPharm Labs wholly owned subsidiary Harvest Medicine has published a study in the peer-reviewed American Journal of Endocannabinoid Medicine. This is the largest peer reviewed published study of its kind on Fibromyalgia and cannabis, with over 800 patient assessments. Between baseline and follow-up appointments, 75% of patients saw a ... Read More...

MediPharm Labs begins restructuring immediately following completion of its acquisition of VIVO and reiterates confidence in $7 to 9M of projected annualized synergies. (1)(2)(3)(4) MediPharm Labs appoints Michael Bumby, former Chief Financial Officer of VIVO, to the Board of Directors of MediPharm. BARRIE, ON, April 13, 2023 - MediPhar... Read More...

MediPharm Labs shares progress on clinical trials, including the provision of clinical trial materials and research support to multiple partners. Research support consists of both product and services for partner studies across various indications. MediPharm Labs participation ranges from full drug development support to FDA approved cli... Read More...

BARRIE, ON, Oct. 7, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, completed the sale of MediPharm Labs Australia Pty ("MediPharm Labs Australia"), a fully owned subsidiary of the Company, for a value of $7.25M AUD ($6.3M CAD) (the ... Read More...

BARRIE, ON, July 27, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, today announced that it has been awarded a favourable summary of judgement in the Ontario Court of Justice in connection with a supply agreement disput... Read More...

BARRIE, ON, July 11, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, has entered into a Share Purchase Agreement (the "Agreement") with OneLife Botanicals PTY ("OneLife Botanicals") for the sale of MediPharm Labs Australia Pty Ltd ("... Read More...

BARRIE, ON, June 30, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual meeting of holders of common shares held on Thursday, June 30, 2022 (the "Meeting"). The voting result... Read More...

BARRIE, ON, April 20, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs", "MediPharm") a pharmaceutical company specializing in precision-based cannabinoids, today announced that it has appointed experienced Pharma and Med Tech executive David Pidduck as Chief Executive Officer and Director of the Company.... Read More...

Naturally derived oil and inhalable cannabigerol ("CBG") products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC. New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains. Launch... Read More...

Completed a Drug Master File ("DMF") process for CBD Active Pharmaceutical Ingredient ("API") for the US Federal Drug Administration ("FDA"). Use of Canadian Drug Establishment Licence ("DEL") to register API with the FDA for commercial opportunities in pharmaceutical development, novel drugs and generic drugs. The cannabis-based drug ... Read More...

BARRIE, Ontario, Dec. 07, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce changes to its Board of Directors (the “Board”). Effectively immediately, Pat McCutcheon, Warren Everitt and Keith Str... Read More...

A leader in CBN products, MediPharm Labs, adds CBN:CBD products to its wellness portfolio for consumers and patients looking for a product without THC effects.New CBN products include CBN:CBD 1:2 Relax Formula Oil and a Northbound high CBN and high CBD vape cartridge. BARRIE, Ontario, Nov. 23, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTC... Read More...

Received first instalment of a government grant for $330,000AUD as part of the Australian government’s Manufacturing Modernisation program aimed at supporting manufacturers scaling their businesses.Grant to be used for automation of downstream manufacturing and scaling purification abilities.Government grant as part of broader manufacturi... Read More...

Completed the regulatory process required to ship medical cannabis to Brazil with import permits issued from ANVISA and export permits issued from Health Canada. Initial deliveries will be under the compassionate care program.First shipments to Brazil to be used for patient trials to collect data that may be used in future product marketi... Read More...

Health Canada Drug Establishment Licence allows MediPharm Labs to conduct pharmaceutical manufacturing and sale of Active Pharmaceutical Ingredients and Pharmaceutical Drug ProductsMakes MediPharm Labs a full-service pharmaceutical company that can support the global pharma entry into the drugs containing cannabis market, including in the... Read More...